Finding. Mitochondrial calcium uniporter activators that actually work are rare. Caldero-Escudero, Santo-Domingo, De la Fuente and colleagues screened 1,280 bioactive compounds and pulled CGP7930. It drives mitochondrial Ca2+ uptake, and it needs MICU1, not MICU2. Docking and mutagenesis put the compound on MICU1 Gln304 and Val307. It also multiplies mitochondria-ER contact sites, a second on-ramp for calcium. In cardiomyocytes, energy metabolism wakes up in a calcium-dependent way. Perfused mouse hearts contract harder. MCU-knockout hearts do not.
Why this paper matters
The uniporter is how the matrix hears a cytosolic calcium spike and pays ATP forward. Genetics of MCU, MICU1, and EMRE are rich. Pharmacology is poor. An activator with a subunit requirement and a residue pair is a tool the field can argue with. An MCU-knockout heart that refuses the inotropy is the control that keeps the story from being “stimulant plus wishful thinking.”
The extra ER contacts are not decoration. If the compound both opens the uniporter and walks the ER closer, you have a dual calcium-delivery drug. That is powerful and dangerous. Healthy hearts may like it. Injured ones may load the matrix and die.
How to read the score
Low nineties. Screen, mechanism, mutagenesis, whole-heart MCU dependence. Confidence is high for acute MCU-dependent force, lower for clinical inotropy and for CGP7930 purity of target.
Caveats
CGP7930 has a life outside mitochondria. Calcium overload is the obvious toxicity. Do not infuse this into a patient from this brief.
What to do with it
If you work on MCU or cardiac excitation-bioenergetics coupling, this is the weekly tool compound. If you build screens, steal the MICU1-versus-MICU2 split and the KO-heart filter. Pull Q304/V307 and the force traces.